Print this page

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with mFOLFIRINOX in Participants with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression.

To evaluate the safety and tolerability of ASP2138 as monotherapy and in combination with pembrolizumab and mFOLFOX6, ramucirumab and paclitaxel and mFOLFIRINOX only.

To determine the MTD and/or the RP2D regimen(s) of ASP2138 as monotherapy and
in combination with pembrolizumab and mFOLFOX6, ramucirumab and paclitaxel and mFOLFIRINOX only.

Protocol Number: 072305
Phase: Phase I
Applicable Disease Sites: Pancreas
Drugs Involved: ASP2138
Principal Investigator: Howard Hochster M.D
Scope: National
Therapies Involved: Chemotherapy single agent systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria ►

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.